Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus INFLAMASE MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus INFLAMASE MILD.
INFLAMASE FORTE vs INFLAMASE MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
N/A
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid